Dipeptide Peptidase 4 (DPP-4) Inhibitors are a class of oral diabetes drugs that work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite. So by protecting incretins from damage, DPP-4 inhibitors help regulate blood glucose levels.
Januvia (Sitagliptin), Galvus (Vildagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin) are the major DPP-4 drugs in the market.

The global Dipeptide Peptidase 4 (DPP-4) Inhibitors market was valued at US$ 9040.4 million in 2019 and is expected to reach US$ 10600 million by the end of 2026, growing at a CAGR of 2.3% during 2021-2026.
This report focuses on Dipeptide Peptidase 4 (DPP-4) Inhibitors volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Dipeptide Peptidase 4 (DPP-4) Inhibitors market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Sitagliptin
Saxagliptin
Linagliptin
Alogliptin
Vildagliptin

Segment by Application
Hospitals
Clinics

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Merck
Eli Lilly
AstraZenica
Boehringer Ingelheim
Takeda Pharmaceutical Company
BMS